BETA

14 Amendments of Sophie AUCONIE related to 2011/0429(COD)

Amendment 99 #
Proposal for a directive
Article 2 – point 4
Directive 2008/105/EC
Article 8 – paragraph 1 a (new)
The Commission shall demonstrate evidence of EU and ecotoxicological relevance when identifying priority hazardous substances.The Commission shall establish criteria for the selection of PHS which shall take into account criteria defining persistence, bioaccumulation and toxicity in water and sediment as is contained in the relevant EU legislation, the EU specific legislation for substances where applicable, or relevant international agreements.
2012/11/13
Committee: ENVI
Amendment 124 #
Proposal for a directive
Article 2 – point 6
Directive 2008/105/EC
Article 8 b – paragraph 2
2. The Commission shall be empowered to adopt delegated acts in accordance with Article 10 concerning the drawing up of the watch list referred to in paragraph 1 of this Article. The Commission shall establish the criteria and procedure to remove from the watch list any substance for which monitoring indicates that there is not sufficient evidence or relevance at EU level or ecotoxicologically.
2012/11/13
Committee: ENVI
Amendment 229 #
Proposal for a directive
Recital 8 a (new)
(8a) Studies show that medicine residues can pose risks to aquatic environments. This matter should therefore be dealt with at European level without delay in order to secure the best cost-benefit ratio. Risks should be assessed more thoroughly using accurate monitoring data comparable on a Union-wide basis. The watch list system under this Directive should enable the necessary data to be gathered for the future review of the list of priority substances. By virtue of Article 16(9) of Directive 2000/60/EC, the Water Framework Directive, the Commission is called upon to draw up a European strategy to combat pollution of water by medicines. It should accordingly submit proposals serving to improve risk assessment at the time when the drugs concerned are placed on the market and to identify the measures which could most effectively reduce the risks to an acceptable level. It should make use of the Common Implementation Strategy for the Water Framework Directive and of the bodies involved in the monitoring of emerging environmental substances (NORMAN) and the Joint Research Centre.
2012/11/08
Committee: ENVI
Amendment 244 #
Proposal for a directive
Article 2 – point 6
Directive 2008/105/EC
Article 8 b – paragraph 2
2. The Commission shall be empowered to adopt delegated acts in accordance with Article 10 concerning the drawing-upcompletion and any subsequent updating of the watch list referred to in paragraph 1 of this Article.
2012/11/08
Committee: ENVI
Amendment 245 #
Proposal for a directive
Article 2 – point 6
Directive 2008/105/EC
Article 8 b – paragraph 3
3. The Commission shall draw up the first watch list as referred to in paragraph 1 by[…], containing the substances already listed in Annex II, shall be completed by the Commission by[…] and thereafter updated where necessary.
2012/11/08
Committee: ENVI
Amendment 248 #
Proposal for a directive
Article 2 – point 6
Directive 2008/105/EC
Article 8 b – paragraph 4 – subparagraph 1
4. Member States shall monitor each substance in the watch list at selected representative monitoring stations over at least a 126-month period commencing within 3 months of its inclusion in the watch list.
2012/11/08
Committee: ENVI
Amendment 251 #
Proposal for a directive
Article 2 – point 6 a (new)
Directive 2008/105/EC
Article 8 c (new)
6a. The following Article 8c is inserted: ‘Article 8c Specific provisions for pharmaceutical substances Pursuant to Article 16(9) of Directive 2000/60/EC, the Commission shall, within two years, draw up a strategy against pollution of water by pharmaceutical substances. The strategy shall include: - proposals enabling, to the extent necessary, the environmental impacts of medicines to be taken into account more effectively in the procedure for placing medicinal products on the market (Directive 2001/83/EC, Directive 2011/83/EU, Regulation (EC) No 726/2004); - an assessment of the risks associated with the presence of medicines in aquatic environments and proposals to reduce them; - information with which to calculate the cost-effectiveness ratio of the measures proposed. In order to draw up the above strategy, the Commission shall make use of the committee referred to in Article 21 of Directive 2000/60/EC.
2012/11/08
Committee: ENVI
Amendment 256 #
Proposal for a directive
Annex I – table – row 46
Directive 2000/60/EC
Annex X – table – row 46
(46) 57-63-6 200-342-2 17alpha-ethinylestradiol deleted
2012/11/08
Committee: ENVI
Amendment 258 #
Proposal for a directive
Annex I – table – row 47
Directive 2000/60/EC
Annex X – table – row 47
(47) 50-28-2 200-023-8 17beta-estradiol deleted
2012/11/08
Committee: ENVI
Amendment 260 #
Proposal for a directive
Annex I – table – row 48
Directive 2000/60/EC
Annex X – table – row 48
(48) 15307-79-6 239-346-4 Diclofenac deleted
2012/11/08
Committee: ENVI
Amendment 286 #
Proposal for a directive
Annex II – table – row 46
(46) 17alpha-ethinylestradiol 57-63-6 3,5 10-5 7 10-6 not not applic applic able able deleted
2012/11/08
Committee: ENVI
Amendment 288 #
Proposal for a directive
Annex II – table – row 47
Directive 2008/105/EC
Annex I – table – row 47
(47) 17beta-estradiol 50-28-2 4 10-4 8 10-5 not not applic applic able able deleted
2012/11/08
Committee: ENVI
Amendment 290 #
Proposal for a directive
Annex II – table – row 48
Directive 2008/105/EC
Annex I – table – row 48
(48) Diclofenac 15307-79-6 0,1 0,01 not not applicable applicable deleted
2012/11/08
Committee: ENVI
Amendment 295 #
Proposal for a directive
Annex II a (new)
Directive 2008/105/EC
Annex II (new)
ANNEX II a ‘ANNEX IIa SUBSTANCES TO BE INCLUDED IN THE FIRST WATCH LIST DRAWN UP BY THE COMMISSION CAS number1 EU number2 Name of substance 1066-51-9 not applicable Amino-methyl phosphonic acid (AMPA) 298-46-4 206-062-7 Carbamazepine 57-12-5 not applicable Free cyanide 1071-83-6 213-997-4 Glyphosate 15687-27-1 239-784-6 Ibuprofen 3380-34-5 222-182-2 Triclosan 9029-97-4 231-175-3 Zinc and its compounds 57-63-6 200-342-2 17alpha-ethinylestradiol 50-28-2 200-023-8 17beta-estradiol 15307-79-6 239-346-4 Diclofenac __________________________ 1 CAS: Chemical Abstracts Service. 2 EU number: European Inventory of Existing Commercial Substances (EINECS) or European List of Notified Chemical Substances (ELINCS).’
2012/11/08
Committee: ENVI